|
Improved Human Methylthioadenosine/Adenosine (MTA/ADO) Depleting Enzyme Variants for Cancer Therapy
The technology involves engineered polypeptides (and their compositions, nucleic acids, expression vectors, host cells and methods) that degrade methylthioadenosine and adenosine to treat cancers with MTAP gene deletions. These polypeptides are conjugated with polymers like PEG to enhance their stability and reduce immunogenicity, improving immune...
|
|
Producing modified lipid A bacterial vaccine components
Engineered bacteria are designed to produce modified lipid A with reduced toxicity and either polypeptide or polysaccharide antigens, which can be used in vaccines to elicit targeted immune responses.
Background
The challenge of developing effective vaccines against bacterial infections lies in the dual necessity of eliciting a robust immune response...
|
|
Biotechnological approach for cancer treatment through kynurenine depletion using engineered enzymes
This invention describes engineered kynureninase enzymes that degrade kynurenine, a metabolite linked to cancer progression. These enzymes, optimized for human therapy, can be modified with polyethylene glycol to enhance stability and circulation, offering potential in cancer treatment when combined with other therapies like immunotherapy.
Background
Cancer...
|
|
Enhanced cancer treatment through methionine depletion
The invention involves engineering a modified human cystathionine-γ-lyase enzyme to degrade methionine, an amino acid essential for cancer cell growth. This modified enzyme, with specific amino acid substitutions, offers enhanced catalytic activity, stability, and reduced immunogenicity, making it suitable for cancer treatment by depleting methionine...
|
|
Engineered enzymes for treating cancer and severe combined immunodeficiency
The technology describes engineered methylthioadenosine (MTA) and adenosine (ADO)-degrading enzymes from either prokaryotic or mammalian sources to be used in pharmaceutical formulations to treat cancer or severe combined immunodeficiency (SCID) by enhancing pharmacological properties like serum stability and reducing immunogenicity.
Background
The...
|
|
Engineered sugar uptake in yeast cells
The technology focuses on engineered transporter proteins that enhance the uptake of specific monosaccharides like xylose and arabinose into yeast cells, improving their efficiency and selectivity for biofuel and biochemical production.
Background
The efficient conversion of lignocellulosic biomass into biofuels and biochemicals is a critical...
|
|
Metabolic engineering of Yarrowia lipolytica for high‑level polyketide production
Background
The field of biotechnology has seen significant advancements in the use of genetically modified organisms to produce valuable compounds. Polyketides, a diverse class of secondary metabolites, are of particular interest due to their wide-ranging applications in pharmaceuticals, bioactive compounds, and renewable chemicals. Traditional methods...
|
|
Revolutionizing plastic recycling: FAST-PETase enzyme variant
Background
Plastic waste is a pressing ecological challenge, with a staggering 8.3 billion metric tons produced, of which 6 billion tons become waste. Traditional methods of plastic degradation, such as chemical processes, are costly and generate harmful byproducts. Enzymatic degradation presents a sustainable alternative, with poly (ethylene terephthalate)...
|
|
Degradons: target proteins for degradation without ubiquitination
Problem
Targeting specific proteins for degradation is an area of intense research for the treatment of disease. The majority of currently available technologies, such as PROTACs, induce degradation through ubiquitination of target proteins by binding to both the target protein and ubiquitin ligases. However, this requires a ubiquitin ligase to efficiently...
|
